DGX 最新10-Q变化
将 DGX 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-07-23 与上一份 10-Q · 2026-04-22
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +62 | −32 | ~26 | 22 |
| 控制与程序 | 文字有新增/删除 | +43 | −19 | ~47 | 69 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
| 其他信息 | 文字有新增/删除 | +1 | −1 | 0 | 3 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)、法律诉讼
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-07-23
Senior Notes Offering and Repayment of Existing Senior Notes
In May 2026, we completed a senior notes offering consisting of $500 million aggregate principal amount of 5.00% senior notes due June 2036 (the "2036 Senior Notes"), which were issued at an original issue discount of $6 million. On June 1, 2026, the net proceeds from the 2036 Senior Notes and cash …
For further details see Note 7 to the interim unaudited consolidated financial statements.
•pre-tax charges of $4 million ($1 million recorded in cost of services and $3 million recorded in selling, general and administrative expenses), or $0.04 per diluted share, primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and int…
•pre-tax charges of $1 million, principally recorded in other operating expense (income), net, or $0.02 per diluted share, primarily representing a loss associated with the increase in the fair value of the contingent consideration accrual associated with previous acquisitions; partially offset by
相对上期删除的文字 · 来源:10-Q · 2026-04-22
Equity in earnings of equity method investees, net of taxes$4 $18 $(14)(77.5)%
Net income attributable to Quest Diagnostics$252 $220 $32 14.4 %
Diluted earnings per common share attributable to Quest Diagnostics' common stockholders$2.24 $1.94 $0.30 15.5 %
•pre-tax charges of $7 million, principally recorded in equity in earnings of equity method investees, net of taxes, or $0.05 per diluted share, representing the losses associated with changes in the carrying value of our strategic investments;
•pre-tax charges of $7 million ($1 million recorded in cost of services and $6 million recorded in selling, general and administrative expenses), or $0.04 per diluted share, primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and int…
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-07-23
Net income attributable to Quest Diagnostics$320 $282 $572 $502
Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans(20)(18)(38)
The accompanying notes are an integral part of these statements.
For the Three Months Ended June 30, 2025Quest Diagnostics Stockholders’ Equity
For the Six Months Ended June 30, 2025Quest Diagnostics Stockholders’ Equity
相对上期删除的文字 · 来源:10-Q · 2026-04-22
Treasury stock, at cost; 51 shares and 52 shares as of March 31, 2026 and December 31, 2025, respectively
The Company is engaged in a multi-year program called Invigorate, which includes structured plans to drive savings and improve productivity across the value chain, including in such areas as patient services, logistics and laboratory operations, revenue services, information technology and procureme…
The Company's pre-tax restructuring charges for the three months ended March 31, 2026 and 2025 were $7 million and $11 million, respectively, entirely related to employee separation costs associated with various workforce reduction initiatives as the Company continued to restructure its organization…
In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass Memorial Medical Center ("UMass") on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. As of March …
The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses approximate fair value based on the short maturities of these instruments. As of March 31, 2026 and December 31, 2025, the fair value of the Company’s debt was estimated at $5.6 billion …
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-07-23
* Includes shares of common stock to be released from (a) stock options and/or restricted stock units that are expected to vest and/or (b) performance share awards that may vest, subject to the satisfaction of the applicable performance metrics. The actual number of shares of common stock that will …
相对上期删除的文字 · 来源:10-Q · 2026-04-22
* Includes shares of common stock to be released from stock options.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议